Related Experiment Video
Updated: Jul 15, 2026

Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
Published on: March 14, 2019
A Trojan-Horse Peptide-Carboxymethyl-Cytidine Antibiotic from Bacillus amyloliquefaciens
Marina Serebryakova1,2, Darya Tsibulskaya1, Olga Mokina1,3
1Institute of Gene Biology, Russian Academy of Science , 34/5 Vavilov str., 119334 Moscow, Russia.
Abstract:
Microcin C and related antibiotics are Trojan-horse peptide-adenylates. The peptide part is responsible for facilitated transport inside the sensitive cell, where it gets processed to release a toxic warhead-a nonhydrolyzable aspartyl-adenylate, which inhibits aspartyl-tRNA synthetase. Adenylation of peptide precursors is carried out by MccB THIF-type NAD/FAD adenylyltransferases. Here, we describe a novel microcin C-like compound from Bacillus amyloliquefaciens. The B. amyloliquefaciens MccB demonstrates an unprecedented ability to attach a terminal cytidine monophosphate to cognate precursor peptide in cellular and cell free systems. The cytosine moiety undergoes an additional modification-carboxymethylation-that is carried out by the C-terminal domain of MccB and the MccS enzyme that produces carboxy-SAM, which serves as a donor of the carboxymethyl group. We show that microcin C-like compounds carrying terminal cytosines are biologically active and target aspartyl-tRNA synthetase, and that the carboxymethyl group prevents resistance that can occur due to modification of the warhead. The results expand the repertoire of known enzymatic modifications of peptides that can be used to obtain new biological activities while avoiding or limiting bacterial resistance.
Insights
Researchers discovered a new microcin C-like antibiotic from Bacillus amyloliquefaciens. This novel compound targets aspartyl-tRNA synthetase and features carboxymethylation to prevent bacterial resistance.
Area of Science:
- Microbiology
- Biochemistry
- Molecular Biology
Background:
- Microcin C is a Trojan-horse peptide-adenylate antibiotic.
- It inhibits aspartyl-tRNA synthetase after intracellular processing.
- Adenylation of peptide precursors is catalyzed by MccB THIF-type NAD/FAD adenylyltransferases.
Purpose of the Study:
- To characterize a novel microcin C-like compound from Bacillus amyloliquefaciens.
- To investigate the enzymatic modifications involved in its synthesis.
- To assess its biological activity and potential for overcoming resistance.
Main Methods:
- In vitro and cellular assays using Bacillus amyloliquefaciens.
- Enzymatic assays to study MccB and MccS activity.
- Analysis of microcin structure and function.
Main Results:
- Bacillus amyloliquefaciens MccB attaches a terminal cytidine monophosphate to precursor peptides.
- The cytosine moiety is further modified by carboxymethylation, mediated by MccB and MccS.
- These modified microcin C-like compounds are active against aspartyl-tRNA synthetase and resist common resistance mechanisms.
Conclusions:
- A novel class of microcin C-like antibiotics with terminal cytosine modifications has been identified.
- Carboxymethylation of the cytosine moiety is a key modification that enhances biological activity and prevents resistance.
- These findings expand the known repertoire of peptide modifications for developing new antibiotics.
More Related Videos
09:26Identification of Antibacterial Immunity Proteins in Escherichia coli using MALDI-TOF-TOF-MS/MS and Top-Down Proteomic Analysis
Published on: May 23, 2021
08:58Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Related Concept Videos
Special Staining Techniques
Bacterial Phylum Spirochaetes
Bacterial Phylum Actinobacteria
Tetanus
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance